347174-29-2

Upstream product

• 347174-27-0 methyl 2-[4-(2-bromo-5-tert-butoxycarbonylbenzyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate 
• 1679-18-1 4-Chlorophenylboronic acid 
• 7697-28-1 4-bromo-3-methylbenzoic acid 
• 503859-17-4 2-bromo-5-(tert-butoxycarbonyl)benzyl bromide 
• 347174-28-1 tert-butyl 4-bromo-3-methylbenzoate 

Downstream Products

• 347174-31-6 methyl 2-{4-[2-(4-chlorophenyl)-5-methylcarbamoylbenzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylate 
• 347174-30-5 2-[4-(4-carboxy-4'-chlorobiphenyl-2-ylmethoxy)phenyl]-1-cyclohexyl-1H-benzimidazole-5-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: Structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109

Following the discovery of a new series of benzimidazole derivatives bearing a diarylmethyl group as inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase (HCV NS5B RdRp), we extended the structure-activity relationship (SAR) study to analogue

Fused-ring compounds and use thereof as drugs

The present invention provides a fused ring compound of the following formula [I] wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and a therapeutic agent for hepatitis C, which contains this compound. Th